Viridian Therapeutics to Participate in June Investor Conferences
2022年6月1日 - 9:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology
company advancing new treatments for patients suffering from
serious diseases underserved by current therapies, today announced
that Jonathan Violin, Ph.D., President and Chief Executive Officer
of Viridian, will participate in two fireside chats at the
Jefferies Healthcare Conference being held in New York on June 8
-10, 2022 and the JMP Securities Life Sciences Conference in New
York on June 15 - 16, 2022.
Jefferies Healthcare Conference |
|
Format: |
Fireside Chat |
Date: |
Wednesday, June 8 |
Time: |
11:30 am ET |
Webcast link: |
Registration link |
JMP
Securities Life Sciences Conference |
|
Format: |
Fireside Chat |
Date: |
Wednesday, June 15 |
Time: |
3:30 pm ET |
Webcast link: |
Registration link |
The live webcast and a replay of the fireside chats can also be
accessed under “Events” in the Investors section of the Viridian
Therapeutics website.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases but
underserved by today’s therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). Viridian’s second product candidate, VRDN-002, is a
distinct anti-IGF-1R antibody that incorporates half-life extension
technology and is designed to support administration as a
convenient, low-volume, subcutaneous injection. TED is a
debilitating autoimmune disease that causes inflammation and
fibrosis within the orbit of the eye which can cause double vision,
pain, and potential blindness. Patients with severe disease often
require multiple remedial surgeries to the orbit, eye muscles and
eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media ContactJohn JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 6 2024 まで 7 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 7 2023 まで 7 2024